Davern Capital Partners, LP

CIK 2003147 · View on SEC EDGAR ↗

Portfolio value
$586.5M
#3,428 of 9,443 by 13F value · top 36.3%
Positions
15
As of
June 30, 2026

Portfolio value QoQ: +60.9% 13F does not disclose cash

Top 10 holdings weight
86.76%
Top 25 holdings weight
100.00%
Positions above 1%
15
Effective number of positions
11.4

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 25.32% Est. buys $318,570,927 · sells $120,397,760

New positions
3
Increased
10
Decreased
2
Closed
5
On this page

Performance vs S&P 500

Tracked Q4 2025–Q2 2026
+10.7%
S&P 500 total return (same window)
+8.7%
Excess return
+2.0%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 98.9% · Options excluded: 0.0%

Sector breakdown

Healthcare
97.6%
Other/Unmapped
2.4%

Full portfolio 15 positions

Type Streak 8Q trend
BNTX BioNTech SE - American Depositary Shares $70,210,878 11.97% 754,550 $43,097,590 Up ×1
ROIV Roivant Sciences Ltd. - Common Shares $68,405,473 11.66% 1,932,904 $44,212,348 Up ×1
RPRX Royalty Pharma plc - Class A Ordinary Shares $64,806,211 11.05% 1,155,809 $39,861,379 Up ×1
IONS Ionis Pharmaceuticals, Inc. - Common Stock $63,329,637 10.80% 798,709 $34,277,091 Up ×2
INSM Insmed Incorporated - Common Stock $59,688,435 10.18% 559,824 $29,835,897 Up ×1
REGN Regeneron Pharmaceuticals, Inc. - Common Stock $57,764,746 9.85% 92,640 $23,150,474 Up ×1
LEGN Legend Biotech Corporation - American Depositary Shares $34,411,155 5.87% 1,191,522 $10,627,364 Down ×1
ALNY Alnylam Pharmaceuticals, Inc. - Common Stock $34,041,978 5.80% 113,085 Up ×1
NTRA Natera, Inc. - Common Stock $32,295,764 5.51% 118,975 $3,504,004 Down ×1
GPCR Structure Therapeutics Inc. - American Depositary Shares $23,939,987 4.08% 446,059 $17,844,567 Up ×1
MLYS Mineralys Therapeutics, Inc. - Common Stock $23,169,156 3.95% 858,753 $11,055,781 Up ×2
VERA Vera Therapeutics, Inc. - Class A Common Stock $21,404,881 3.65% 498,832 Up ×1
Unknown issuer (CUSIP: 370920100) $13,912,335 2.37% 824,679 $6,514,835 Up ×1
PRCT PROCEPT BioRobotics Corporation - Common Stock $10,497,894 1.79% 464,920 $3,965,282 Up ×1
AVTX Avalo Therapeutics, Inc. - Common Stock $8,660,948 1.48% 468,666 Up ×1

Biggest new bets

New positions opened this quarter, largest first.

Security Value Shares % of portfolio
ALNY $34,041,978 113,085 5.80%
VERA $21,404,881 498,832 3.65%
AVTX $8,660,948 468,666 1.48%

Top movers (QoQ)

Security Action Shares Δ Value Δ
ROIV Bought more +1.1M +$44.2M
BNTX Bought more +449K +$43.1M
RPRX Bought more +636K +$39.9M
IONS Bought more +412K +$34.3M
INSM Bought more +377K +$29.8M
REGN Bought more +48K +$23.2M
GPCR Bought more +320K +$17.8M
MLYS Bought more +412K +$11.1M
LEGN Trimmed -123K +$10.6M
Bought more +233K +$6.5M

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarter Shares before Value before Price since exit
PFE June 30, 2026 1,593,942 $44,757,891 15.6%
ARGX June 30, 2026 35,045 $25,591,611 11.2%
LLY June 30, 2026 27,279 $25,090,406 5.7%
ABVX June 30, 2026 78,125 $8,699,219 -11.7%
CGON March 31, 2026 162,005 $6,726,448 16.6%
VRDN June 30, 2026 302,457 $5,916,059 31.5%